Paraspinous Block, Pelvis Pain Chronic
Conditions
Keywords
Paraspinous block, Non-responsive chronic pelvic pain
Brief summary
This study examines randomized triple-blind clinical trial and the efficacy of paraspinous anesthetic block on the treatment of chronic pelvic pain in patients non-responsive to pharmacological management. Sixty patients will be randomly divided and allocated into group intervention (paraspinous anesthetic block) and control (placebo procedure in subcutaneous tissue).
Detailed description
Patients will be allocated into one of two groups (intervention or placebo), and will be submitted to the corresponding procedure (paraspinous anesthetic block or placebo puncture in subcutaneous tissue). In the first appointment, pain will be measured with the VAS (Visual Analogue Scale); quality of life and function basal level will be evaluated by scales SF-36 (Medical Outcome Short-Form (36)Health Survey)and FSFI (Female Sexual Function Index), in Portuguese validated versions. Procedure will be realized as planned for each group. Second appointment will occur one week after the procedure, and VAS scale will be applied. Third appointment will occur in one month. VAS scale will be applied again,and procedure will be repeated if patient does not have a reduction of at least 30% of pain. Next consultations will occur at two months, three months, four months and five months, with application of VAS scale to keep monitoring evolution of pain. At six months of study, VAS scale will be applied along with SF-36 and FSFI questionnaires, to evaluate improvement in pain and in quality of life and function level.
Interventions
PROCEDUREparaspinous anesthetic block
Paraspinous anesthetic block with lidocaine 1% in sensitized segments of the thoracolumbar region
PROCEDUREsubcutaneous puncture with no anesthetic effect
Subcutaneous puncture with injection needle (no substance will be injected)
Sponsors
Hospital de Clinicas de Porto Alegre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with benign pelvic pain non-responsive to pharmacological treatment, lasting at least 6 months, located in the anatomic pelvis, anterior abdominal wall, infra-umbilical region, lumbossacral region or buttocks. Pain must be hard enough to cause functional impairment or to motivate medical counseling. The absence of physical findings does not decreases the importance of pain, nether excludes the possibility of pelvic pathology.
Exclusion criteria
* Patients who do not want to take part in the study * Age under 18 years old * Pelvic pain lasting less than 6 months * Relief or resolution of pain with pharmacological treatment * Pain of neoplastic origin * Known allergy or report of adverse reaction related to lidocaine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of pain from baseline | Change of pain from baseline at one week, at one month, at two months, at three months, at four months, at five months and at six months | Primary outcome is the reduction of pain, measured with the Visual Analogue Scale (VAS). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of scores in SF-36 scale | At baseline and at six months | Quality of life will be evaluated with SF-36 scale at baseline and at six months, and scores will be compared at the end of the study. |
| Improvement of scores in the FSFI scale | At baseline and at six months | Sexual function as a measure of functionality will be evalueted with the FSFI scale at baseline and at six months, and scores will be compared at the end of the study. |
Countries
Brazil
Outcome results
None listed